Biosimilar and interchangeable are different findings

This blog has already drawn one line between what a special status buys and what it doesn't, in breakthrough designation's speed without an approval, and another between a mechanism that binds a prescriber's practice and a label that only advises it, in the REMS that binds more tightly than a label can. FDA's biosimilar pathway draws a similar line inside a single application. A biosimilar approval and an interchangeable designation are two separate findings, made against two different legal standards, and only one of them changes what happens at the pharmacy counter.

Biosimilarity is the floor every biosimilar has to clear

The Biologics Price Competition and Innovation Act, enacted in 2010, created section 351(k) of the Public Health Service Act as a licensure pathway for biosimilars: a product FDA finds highly similar to an already-licensed reference product, with no clinically meaningful differences in safety, purity, or potency. Every biosimilar approved under 351(k) has cleared that finding. It's the baseline the whole pathway rests on, and by itself it says nothing about whether a pharmacist can swap the biosimilar in for the reference product without checking with the prescriber first.

Interchangeability asks a second, harder question

Section 351(k)(4) lets a sponsor seek a separate interchangeability designation on top of biosimilarity, and the standard is higher: the product has to be expected to produce the same clinical result as the reference product in any given patient, and for a product given more than once, the risk of switching back and forth between the biosimilar and the reference product can't be greater than the risk of staying on the reference product alone. Biosimilarity is a comparison of the two products. Interchangeability is a prediction about what happens to a specific patient who moves between them, which is a different kind of evidence question even when the underlying molecule hasn't changed at all.

The only thing the designation actually unlocks is pharmacy-level substitution

An interchangeable designation's practical effect is narrow and specific: it lets a pharmacist dispense the interchangeable product in place of the prescribed reference product without contacting the prescriber first, subject to the substitution rules each state sets on top of the federal finding. A biosimilar without that designation can still be prescribed, covered, and used exactly like the reference product — a prescriber who wants a patient on a particular biosimilar can simply write for it by name. What a plain biosimilar can't do is get swapped in at the counter the way a generic drug routinely is; that substitution right belongs to interchangeability alone.

FDA has been lowering the bar to reach that second finding

FDA's 2019 guidance on demonstrating interchangeability generally recommended a switching study — direct evidence of patients alternating between the biosimilar and the reference product — as part of that higher-standard showing. In June 2024, FDA issued draft guidance proposing to drop that general recommendation, reasoning that nine of the thirteen interchangeable biosimilars approved by that point had reached the designation without one, relying instead on an assessment of the product's existing analytical and clinical data. That guidance was still in draft as of this writing, and a sponsor building its evidence package should check its current status rather than assume the switching-study expectation is gone industry-wide.

A biosimilar tracker needs its own field for the second finding

A regulatory file built around a single “biosimilar approved” milestone has no place to record that interchangeability is a separate determination — one that can be requested inside the original application, held back for a later supplement, or split off entirely if the data supports biosimilarity but falls short on the higher standard — with its own review and its own date. A tracker that only distinguishes “biosimilar” from “not yet approved” will tell a formulary or a pharmacy exactly the wrong thing about whether substitution is actually permitted, because the dividing line a pharmacy needs sits one finding deeper than the one the tracker recorded.

Where this meets the file

A biosimilar tracking template that keeps interchangeability as its own required field — separate from, and not implied by, the underlying biosimilarity approval — is previewed in the launch catalog alongside this week's other drug-lifecycle templates. If your program tracks that distinction differently, the shelf takes that correction directly.